Evaluation of detection and characterization of liver tumor with 3D rapid acquisition sequence with compressed sensing
Not Applicable
Recruiting
- Conditions
- liver tumor
- Registration Number
- JPRN-UMIN000035896
- Lead Sponsor
- Tokyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with allergic history with bronchial asthma or past nonspecific extracellular fluid contrast agents or hepatocyte specific contrast agents. 2. Patients with impaired renal function. 3. Patients with internal metals. 4. Claustrophobia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does 3D rapid acquisition with compressed sensing improve liver tumor detection compared to standard MRI protocols?
What imaging biomarkers are associated with liver tumor characterization using compressed sensing MRI in JPRN-UMIN000035896?
Are there specific molecular features of hepatocellular carcinoma or cholangiocarcinoma detectable via 3D compressed sensing sequences?
What adverse events are reported with 3D rapid acquisition MRI in liver tumor patients at Tokyo Medical University?
How does compressed sensing MRI compare to contrast-enhanced CT for liver tumor staging and treatment monitoring?